Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for KMDA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 269.56M
March 31, 2026 259.39M
December 31, 2025 269.07M
September 30, 2025 265.23M
June 30, 2025 259.95M
March 31, 2025 251.96M
December 31, 2024 259.46M
September 30, 2024 255.27M
June 30, 2024 251.15M
March 31, 2024 246.51M
December 31, 2023 244.02M
September 30, 2023 238.39M
June 30, 2023 176.75M
March 31, 2023 174.81M
December 31, 2022 176.02M
September 30, 2022 172.55M
June 30, 2022 171.57M
March 31, 2022 175.15M
December 31, 2021 176.82M
September 30, 2021 181.61M
June 30, 2021 182.34M
March 31, 2021 181.22M
December 31, 2020 178.64M
September 30, 2020 176.73M
June 30, 2020 169.76M
Date Value
March 31, 2020 165.82M
December 31, 2019 135.32M
September 30, 2019 130.14M
June 30, 2019
March 31, 2019 117.47M
December 31, 2018 112.38M
September 30, 2018 93.92M
June 30, 2018 95.90M
March 31, 2018 90.11M
December 31, 2017 89.49M
September 30, 2017 83.71M
June 30, 2017 68.34M
March 31, 2017 63.22M
December 31, 2016 66.74M
September 30, 2016 68.67M
June 30, 2016 69.39M
March 31, 2016 70.87M
December 31, 2015 72.51M
September 30, 2015 69.97M
June 30, 2015 74.12M
March 31, 2015 74.67M
December 31, 2014 79.27M
September 30, 2014 76.38M
June 30, 2014 78.43M
March 31, 2014 85.69M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
BioLineRx Ltd. 16.67M
XTL Biopharmaceuticals Ltd. --
Can-Fite BioPharma Ltd. --
Galmed Pharmaceuticals Ltd. 13.95M
Revium Recovery, Inc. 18.10M

Shareholders Equity (Quarterly) Related Metrics